Insight
Life Sciences Snapshot – Q4 2024 – A Quarterly Report on Financing Trends
14 minute read | December.20.2024
Healthtech Horizons: Navigating Regulation, Investment, and Strategy in a Transforming Market
14 minute read | December.20.2024
Healthtech Horizons: Navigating Regulation, Investment, and Strategy in a Transforming Market
28 minute read | October.07.2024
by Stephen Thau and Mike O'Donnell
3 minute read | September.26.2024
by Stephen Thau and David Sharrow
4 minute read | September.23.2024
21 minute read | June.26.2024
by Stephen Thau, Paul F. Rugani and Nina Ganti
1 minute read | April.09.2024
Companies should review insider-trading policies after an SEC enforcement action put "shadow trading" in the spotlight.
25 minute read | February.26.2024
Women's & Reproductive Health
by Stephen Thau, Albert Vanderlaan and George Pothoulakis
6 minute read | January.30.2024
Reverse mergers have helped biotech companies access public markets, but recent SEC positions are threatening that path to going public.
by David Rhinesmith, Thora Johnson, Stephen Thau and Tony Chan
4 minute read | November.10.2023
22 minute read | November.10.2023
20 minute read | July.25.2023
26 minute read | April.25.2023
This edition of Orrick’s life sciences publication series reviews key trends of venture investment in the life sciences industry during Q1 2023.